5 September, 2017 by The TZ Newswire Staff Comments Off on Simple Charts Showing Why Gold Stocks Are Poised To Blast Off
Simple Charts Showing Why Gold Stocks Are Poised To Blast Off
When gold began to rally in late 2015, investors breathed a sigh of relief. The longest resource bear market was finally over, and capital slowly began finding its way back into the mining sector.
5 September, 2017 by The TZ Newswire Staff Comments Off on Why Himax Technologies, Inc. Popped 19% in August
Why Himax Technologies, Inc. Popped 19% in August
Last month, Himax Technologies, Inc. (NASDAQ: HIMX) stock price jumped 19%, according to data provided by S&P Global Market Intelligence, likely on news that the company is collaborating with Qualcomm (NASDAQ: QCOM) on new 3D depth-sensing camera technology and investors’ optimism that the company’s tech will be inside Apple‘s newest iPhones, which will debut next week.
5 September, 2017 by The TZ Newswire Staff Comments Off on IRMA > Un: Class-5 weather so much bigger than Fat Boy’s Fat Man.
IRMA > Un: Class-5 weather so much bigger than Fat Boy’s Fat Man.
Wow.
12 noon the NWS updated on Irma, and in the next 15 minutes, the SPX dropped from -10 pts to -23pts, and is now down -30pts.
Equal drops across the NDX and DJIA and RUT.
Not so curiously, the TRIN has climbed, but remains buy-volume-weighted at 0.78.
The seal on the deal? The DAX and Eurocentric DJ600 are bracketing 0.00% for the day. (Thus, this is a ‘Merican deal, not a global deal.)
VIX is climbing throughout the day, though. So, Irma’s scariness remains. Time to buy HD/LOW/etc….?
5 September, 2017 by The TZ Newswire Staff Comments Off on The ‘Hysteria’ Curve Crashes To 12-Month Lows
The ‘Hysteria’ Curve Crashes To 12-Month Lows
5 September, 2017 by The TZ Newswire Staff Comments Off on Here’s Why Cellectis SA Fell as Much as 31.6% Today
Here’s Why Cellectis SA Fell as Much as 31.6% Today
Shares of biopharma Cellectis (NASDAQ: CLLS) fell nearly 32% today after the company announced that the U.S. Food and Drug Administration had placed a clinical hold on its second leading product candidate, UCART123. The regulatory hold affects two ongoing phase 1 trials aimed at treating acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
5 September, 2017 by The TZ Newswire Staff Comments Off on White House Press Briefing with Sarah Huckabee Sanders
White House Press Briefing with Sarah Huckabee Sanders
White House